Skip to main content

Table 1 Clinical, histological and molecular parameters of 181 node-negative breast cancer patients

From: C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

Parameter

Number of patients (%)

Tumour size

 

   T1

118 (65.2)

   T2

54 (29.8)

   T3/4

9 (5.0)

Age (years)

 

   <40

14 (7.7)

   40–55

46 (25.4)

   >55

121 (66.9)

Histopathological grading

 

   G1

5 (2.8)

   G2

105 (58)

   G3

71 (39.2)

ER status

 

   ER negative

64 (35.4)

   ER positive

115 (63.5)

   Unknown

2 (1.1)

PR status

 

   PR negative

66 (36.5)

   PR positive

112 (61.9)

   Unknown

3 (1.7)

Oncogenes

 

   C-myc nonamplified

142 (78.5)

   C-myc amplified

39 (21.5)

HER-2/neu nonamplified

126 (69.6)

HER-2/neu amplified

55 (30.4)

   C-myc and HER-2/neu coamplified

22 (12.2)

  1. ER, oestrogen receptor; PR, progesterone receptor.